SCHEMBL21144689

SCHEMBL21144689

C[C@H]1CN(CCC(Cc2ccc(C#N)cc2)NC(=O)OC(C)(C)C)CCN1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
CTSS P25774 7/20 0.39
CTSK P43235 6/20 0.39
GPR119 Q8TDV5 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
DRD2 P14416 1/20 0.38
MC4R P32245 1/20 0.38
P2RX7 Q99572 1/20 0.37
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37
PDK4 Q16654 1/20 0.37
CHRM4 P08173 1/20 0.37
PTPN1 P18031 1/20 0.37
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21144890 1.00 ATM (0.40) ATMCTSSCTSKGPR119CTSL
SCHEMBL21144687 1.00 ATM (0.40) ATMCTSSCTSKGPR119CTSL
SCHEMBL21144891 1.00 ATM (0.40) ATMCTSSCTSKGPR119CTSL
SCHEMBL18930773 0.93 GPR119 (0.42) ATMCTSSCTSKGPR119CTSL
SCHEMBL21169852 0.93 GPR119 (0.42) ATMCTSSCTSKGPR119CTSL
SCHEMBL18930771 0.86 ATM (0.43) ATMCTSSCTSKCTSLCTSB
SCHEMBL18930526 0.82 CACNA1B (0.41) ATMCTSSCTSKGPR119CTSL
SCHEMBL21676604 0.82 CACNA1B (0.41) ATMCTSSCTSKGPR119CTSL
SCHEMBL21169944 0.82 CACNA1B (0.41) ATMCTSSCTSKGPR119CTSL
SCHEMBL18930525 0.82 ACACB (0.45) ATMCTSSCTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L ATM 346/4885CTSS 3972/4885CTSK 3752/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L ATM 346/4885CTSS 3972/4885CTSK 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.